Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples
Open Access
- 1 April 1999
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 47 (4) , 397-402
- https://doi.org/10.1046/j.1365-2125.1999.00918.x
Abstract
Aims To validate the use of randomly collected urine samples for assessment of cytochrome P4501A2 (CYP1A2) activity based on dietary caffeine (caffeine metabolic ratio, MRcaff ), and to relate the MRcaff to caffeine intake and smoking habits in a larger group of individuals. Methods Nineteen healthy volunteers were included in the validation study. Caffeine (100 mg) was ingested and a urine sample was collected after 6 h. Within the following week a random urine sample was collected in the individuals without a preceding test dose of caffeine. Urine samples were analysed for caffeine and its metabolites by h.p.l.c. and the (AFMU+1U+1X)/1,7U metabolic ratio was used to reflect CYP1A2 activity. In an extended investigation of 522 healthy pregnant women the MRcaff was related to intake of caffeine from various sources, and to smoking. Results The results from the random and standardised sampling methods correlate with each other (correlation coefficient of MRcaff was 0.91). The MRcaff as assessed by the random sampling method in a larger population was not affected by source or amount of caffeine ingested. Significantly higher MRcaff was found in smokers compared to non-smokers. In the large group of individuals the random sampling method was possible to use in 80% of the cases. In the residual 20% one or several of the metabolite concentrations were too low or unmeasurable. Conclusions Our study demonstrates that the random urine caffeine phenotyping method is possible to use in as many as 80% of the individuals when based on dietary caffeine. Our approach should prove applicable in most countries with widely spread caffeine consumption. The method is useful in larger studies of drug metabolising enzyme activities and minimises the time consumption and costs.Keywords
This publication has 30 references indexed in Scilit:
- Induction of liver and kidney CYP1A1/1A2 by caffeine in ratBiochemical Pharmacology, 1996
- Determination of Urinary Metabolites of Caffeine for the Assessment of Cytochrome P4501A2, Xanthine Oxidase, and N-Acetyltransferase Activity in HumansTherapeutic Drug Monitoring, 1996
- Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessmentPharmacogenetics, 1996
- Induction of hepatic CYP1A2 by the oral administration of caffeine to rats: lack of association with the Ah locusBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1995
- Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activityPharmacogenetics, 1995
- Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.British Journal of Clinical Pharmacology, 1994
- Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of ClozapineTherapeutic Drug Monitoring, 1994
- Caffeine as a probe for human cytochromes P450Pharmacogenetics, 1992
- Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1Pharmacogenetics, 1992
- Foreign compound metabolism capacity in man measured from metabolites of dietary caffeineCarcinogenesis: Integrative Cancer Research, 1992